Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP
Executive Summary
Results of the head-to-head comparison of Pfizer's Lipitor and Bristol-Myers Squibb's Pravachol may reduce industry's enthusiasm for comparative studies, AARP CEO Bill Novelli said
You may also be interested in...
High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests
Results of the IDEAL study support the aggressive use of high-dose statins as standard therapy for patients at high risk of repeat cardiovascular events, Scott Grundy (University of Texas Southwestern Medical Center) told the American Heart Association annual meeting Nov. 15 in Dallas
High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests
Results of the IDEAL study support the aggressive use of high-dose statins as standard therapy for patients at high risk of repeat cardiovascular events, Scott Grundy (University of Texas Southwestern Medical Center) told the American Heart Association annual meeting Nov. 15 in Dallas
Bristol Prepares For Life After Pravachol: Support Will Continue Into 2005
Bristol-Myers Squibb will continue to promote Pravachol over the near term despite declining sales for the statin as wholesalers prepare for generic competition in 2006